|
|
Article: Reports on life sciences findings from Medical University of Vienna, Department of Clinical Pharmacology provide new insights.(Clinical report)
- Article from:
- Biotech Week
- Article date:
- September 24, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Researchers detail in 'Pioglitazone does not affect vascular or inflammatory responses after endotoxemia in humans,' new data in life sciences. According to a study from Vienna, Austria, "PPARgamma agonists have been proposed to exert more than metabolic benefits, particularly by anti-inflammatory mechanisms. We hypothesized that pioglitazone might modulate inflammatory and vascular responses to lipopolysaccharide (LPS)."
"In a placebo-controlled parallel-group study in 18 healthy male subjects, the E. coli endotoxin model of inflammation (20 IU/kg i. v.) was employed to test the effect of 60 mg pioglitazone over nine days on inflammatory cytokines. Macrovascular ...
Related newspaper, magazine, and journal articles:
|
|
Article: Research on life sciences published by scientists ...
Biotech Week;
November 5, 2008 ;
700+ words
... ... Department of Clinical Pharmacology (see also Life Sciences). The researchers ... Dept. of Clinical Pharmacology, Murtenstrasse ... Switzerland, Bern, Life Sciences, Liver Cirrhosis ... Immunology, Clinical Pharmacology, Chromatography ...
|
|